Genmab A (GMAB) EBT (2018 - 2026)

Genmab A (GMAB) has reported EBT for 9 consecutive years, with $295.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 55.77% year-over-year to $295.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.2 billion (down 4.0% YoY), and the FY2025 full-year result was $1.2 billion, down 9.2% from the prior year.
• EBT grew to $295.0 million in Q2 2026 per GMAB's latest filing, from $74.0 million in the prior quarter.
• Across five years, EBT topped out at $2.7 billion in Q3 2023 and bottomed at -$3.8 billion in Q4 2023.
• Historically, EBT has averaged $277.9 million across 5 years, with a median of $266.0 million in 2023.
• The widest YoY moves for EBT: up 245.09% in 2024, down 70.06% in 2024.
• Over 5 years, EBT stood at $253.7 million in 2022, then tumbled by 1602.73% to -$3.8 billion in 2023, then soared by 121.22% to $809.0 million in 2024, then surged by 42.03% to $1.1 billion in 2025, then slumped by 74.33% to $295.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $295.0 million, $74.0 million, and $1.1 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.